HHS Logo U.S. Department of Health & Human Services Divider arrow NIH logo National Institutes of Health Alt desc
Skip Over Navigation Links
Discovering New Therapeutics Uses for Existing Molecules

2014 Industry-Provided Assets

Assets in this table are alphabetized by mechanism of action. These compounds and biologics have undergone significant pre-clinical and safety testing in humans.


2014 Table of Assets for Adult Indications

Code Number & Link to More Information

Mechanism
of Action

Original Development Indication(s)

Route of Administration Formulation Available
(CNS Penetrant+)

AZD4017 (PDF - 155KB)

11-beta hydroxysteroid dehydrogenase type 1 inhibitor

Diabetes

Oral
(Low)

RWJ-445380 (PDF - 108KB)

Cathepsin S inhibitor

Psoriasis
Rheumatoid arthritis

Oral

SAR114137 (PDF - 179KB)

Cathepsin S inhibitor

Chronic pain (osteoarthritis, neuropathic, low back)

Oral
(Maybe)

CNTO-888 (PDF - 141KB)
Carlumab

Chemokine (C-C motif) ligand 2 selective human IgG1 kappa monoclonal antibody

Idiopathic pulmonary fibrosis

Intravenous
(No)

AZD9291 (PDF - 108KB)

Epidermal growth factor receptor (EGFR) tyrosine kinase sensitizing and T790M resistance mutations inhibitor

Non-small cell lung cancer

Oral
(Unknown)

JNJ-31001074 (PDF - 109KB)
Bavisant

Histamine type 3 receptor antagonist

Attention deficit hyperactivity disorder

Oral
(Yes)

SAR110894 (PDF - 112KB)

Histamine type 3 receptor antagonist

Symptomatic treatment of Alzheimer's disease

Oral
(Yes)

AZD2014 (PDF - 126KB)

Mammalian target of rapamycin serine/ threonine kinase (dual TORC1 and TORC2) inhibitor

Solid tumors

Oral
(Unknown)

AZD8529 
(PDF - 108KB)

Metabotropic glutamate receptor 2 positive allosteric modulator

Schizophrenia

Oral
(Yes)

PF-03882845 (PDF - 314KB)

Mineralocorticoid receptor antagonist

Diabetic nephropathy

Oral

AZD6765 (PDF - 129KB)
Lanicemine

N-methyl-D-aspartate receptor open-channel blocker

Major depressive disorder

Intravenous
(Yes)

AZD2624 (PDF - 133KB)

Neurokinin-3 receptor, tachykinin receptor 3 antagonist

Schizophrenia

Oral
(Low)

AZD9668 (PDF - 126KB)

Neutrophil elastase inhibitor

Chronic obstructive pulmonary disease
Cystic fibrosis

Oral
(Low)

PF-03049423 (PDF - 143KB)

Phosphodiesterase type 5 inhibitor

Stroke recovery

Oral
(Yes)

AZD1208 (PDF - 135KB)

Proviral integration Moloney virus serine/threonine kinase family inhibitor

Acute myeloid leukemia
Advanced solid tumors
Malignant lymphoma

Oral
(Yes)

CE-224535 (PDF - 203KB)

Purinergic receptor 2 antagonist

Rheumatoid arthritis
Osteoarthritis

Oral

AZD9150 (PDF - 97KB)

Signal transducer and activator of transcription 3 antisense

Hepatocellular carcinoma

Intravenous
(Low)

AZD1775 (PDF - 183KB)

Wee1 G2 checkpoint kinase inhibitor

Advanced solid tumors

Oral
(Unknown)

+CNS penetrant: Yes, no,maybe, low or unknown.

2014 Table of Assets for Pediatric Indications

Code Number & Link to More Information

Mechanism
of Action

Original Development Indication(s)

Route of Administration Formulation Available
(CNS Penetrant+)

AVE5530 (PDF - 128KB)
Canosimibe

Acyl-coenzyme A: cholesterol O-acyltransferase inhibitor

Hypercholesterolemia

Oral
(No)

SSR149744 (PDF - 125KB)
Celivarone

Cation channel blocker

Supraventricular (atrial fibrillation) and ventricular arrhythmia 

Oral

AZD1981 (PDF - 115KB)

Chemoattractant receptor-homologous molecule expressed on Th2 cells antagonist (prostaglandin D2 receptor antagonist)

Asthma
Chronic obstructive pulmonary disease

Oral
(Low)

AZD7325 (PDF - 153KB)

Gamma-aminobutyric acid receptor A alpha 2 & 3 positive modulator

General anxiety disorder

Oral
(Yes)

AZD3355 (PDF - 167KB)
Lesogaberan

Gamma-aminobutyric acid receptor B agonist

Gastroesophageal reflux disease

Oral
(Low)

JNJ-31001074 (PDF - 109KB)
Bavisant

Histamine type 3 receptor antagonist

Attention deficit hyperactivity disorder

Oral
(Yes)

PF-03654746 (PDF - 192KB)

Histamine type 3 receptor antagonist

Tourette syndrome
Narcolepsy
Cognition
Attention deficit hyperactivity disorder
Allergic rhinitis

Oral
(Yes)

SAR152954 (PDF - 94KB)

Histamine type 3 receptor antagonist

Excessive daytime sleepiness

Oral
(Yes)

AZD6765 (PDF - 129KB)
Lanicemine

N-methyl-D-aspartate receptor open-channel blocker

Major depressive disorder

Intravenous
(Yes)

AZD9668 (PDF - 126KB)

Neutrophil elastase inhibitor

Chronic obstructive pulmonary disease
Cystic fibrosis

Oral
(Low)

JNJ-39393406 (PDF - 118KB)

Nicotinic acetylcholine receptor, α7 positive allosteric modulator

Cognitive impairment associated with schizophrenia

Oral
(Yes)

AZD1775 (PDF - 183KB)

Wee1 G2 checkpoint kinase inhibitor

Advanced solid tumors

Oral
(Unknown)

+CNS penetrant: Yes, no,maybe, low or unknown.

Last updated: 11-08-2017
▲ Back to top